CRL vs OABI
CRL: Charles River Laboratories is a global, non-clinical contract research organization that partners with life sciences companies to streamline drug discovery and development. OABI: OmniAb is an antibody discovery technology leader that provides pharmaceutical partners with proprietary transgenic animal platforms, AI-driven screening, and bioinformatics tools to accelerate the creation of therapeutic biologics.
Side-by-side fundamentals
| Metric | CRL | OABI | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $344.87 | $4.92 | |
| Market cap | $16.5B | $715M | |
| Net margin FY2025, SEC XBRL | -3.6% | -347.0% | CRL higher |
| Operating margin FY2025, SEC XBRL | +0.6% | -369.5% | CRL higher |
| ROE FY2025, SEC XBRL | -4.6% | -24.3% | CRL higher |
| ROA FY2025, SEC XBRL | -2.0% | -21.5% | CRL higher |
| Debt / equity filed borrowings incl. finance leases, balance sheet 2026-06-27 | 0.93 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | -0.8% | -29.3% | CRL higher |
| Revenue CAGR (3y) SEC XBRL | +0.3% | -31.9% | CRL higher |
| Dividend streak (yrs) SEC XBRL | 0 | 1 | OABI higher |
| Beta as of 2026-09-03 | 1.38 | 1.01 | |
| 1-year return as of 2026-10-21 close | +83.2% | +196.1% | OABI higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.